Niagen Bioscience Inc logo NAGE - Niagen Bioscience Inc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 5
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $10.50 DETAILS
HIGH: $11.00
LOW: $10.00
MEDIAN: $10.50
CONSENSUS: $10.50
UPSIDE: 227.10%

Stock News

Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, August 4, 2026.

Jul 21, 2026 04:32 AM • businesswire.com
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026.Dr. Kale will lead Niagen Bioscience's Global Niagen Research Program, overseeing the Company's worldwide network of academic and clinical research collaborations while helping shape its scie.

Jul 16, 2026 04:32 AM • businesswire.com
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicot.

Jul 13, 2026 04:32 AM • businesswire.com
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the C.

Jul 09, 2026 04:32 AM • businesswire.com
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which.

Jul 08, 2026 04:32 AM • businesswire.com
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment.

Jun 03, 2026 04:34 AM • businesswire.com
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Company's name evolution with a focus on advancing the understanding and applications of NAD+ through its flagship ingredient, Niagen® (patented nicotinamide riboside, or NR), the mos.

Jun 02, 2026 04:32 AM • businesswire.com
Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center's Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO.

May 08, 2026 04:32 AM • businesswire.com
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, incl.

May 06, 2026 12:02 PM • businesswire.com
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #AtHomeInjection--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its clinician-directed telehealth platform under Niagen™ Plus, enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride, NRCl) from home with the first-of-its-kind Niagen® At-Home Injection Kit. The launch m.

May 04, 2026 04:32 AM • businesswire.com
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia Pharmaceuticals, a state-of-the-art U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen® (patented nicotinamide riboside, NR) for the Company's Niagen Plus™ intravenous and injectable products. Olympia Pharmaceuticals joi.

Apr 28, 2026 04:32 AM • businesswire.com
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026.

Apr 22, 2026 04:32 AM • businesswire.com
Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy

Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy

Niagen Bioscience is transitioning from supplements to a telehealth-driven longevity platform, targeting higher margins and valuations. I rate NAGE a Strong Buy at around $6-$8 per share, projecting 40% to 75% upside as the Niagen Plus injectable launches and the recurring revenue model matures. NAGE's IP moat, strategic patent acquisition, and direct-to-consumer telehealth strategy position it for premium HealthTech multiples versus supplement peers.

Apr 15, 2026 10:27 AM • seekingalpha.com
Niagen: High-Quality Growth At A Fair Price

Niagen: High-Quality Growth At A Fair Price

Niagen's fiscal 2025 revenue growth and profitability improvement can make the stock attractive for growth-focussed investors. The company's low debt levels and relatively high amount of cash on hand allow them financial flexibility, even during market distress. Macroeconomic headwinds exist, especially low consumer confidence and high energy prices, but share issuance also poses a threat to existing shareholders.

Apr 14, 2026 09:43 PM • seekingalpha.com

Price Targets